Clinical Oncology Education

Revolutionizing Oncology: The Global Roll-Out of AI-Powered Bone Imaging for Advanced Cancer revolutionizing-oncology-the-global-roll-out-of-ai-powered-bone-imaging-for-advanced-cancer

Revolutionizing Oncology: The Global Roll-Out of AI-Powered Bone Imaging for Advanced Cancer

Ali Ikhwan July 17, 2026

In a landmark development for oncology and medical imaging, The Institute of Cancer Research (ICR), London, and...

FDA Expands Scope of Palbociclib: A New Maintenance Strategy for HR+/HER2+ Metastatic Breast Cancer fda-expands-scope-of-palbociclib-a-new-maintenance-strategy-for-hr-her2-metastatic-breast-cancer

FDA Expands Scope of Palbociclib: A New Maintenance Strategy for HR+/HER2+ Metastatic Breast Cancer

Iffa Jayyana July 17, 2026

In a significant development for oncology therapeutics, the U.S. Food and Drug Administration (FDA) has granted approval...

Breakthrough in Pediatric Oncology: Combining Radiopharmaceuticals and CAR T-Cell Therapy to Defeat Solid Tumors breakthrough-in-pediatric-oncology-combining-radiopharmaceuticals-and-car-t-cell-therapy-to-defeat-solid-tumors

Breakthrough in Pediatric Oncology: Combining Radiopharmaceuticals and CAR T-Cell Therapy to Defeat Solid Tumors

Basiran July 16, 2026

In a significant stride toward overcoming one of the most persistent hurdles in modern oncology, researchers at...

FDA Approves Subcutaneous Isatuximab-irfc: A New Era in Multiple Myeloma Treatment fda-approves-subcutaneous-isatuximab-irfc-a-new-era-in-multiple-myeloma-treatment

FDA Approves Subcutaneous Isatuximab-irfc: A New Era in Multiple Myeloma Treatment

Rifan Muazin July 16, 2026

The landscape of multiple myeloma (MM) management has undergone a significant evolution following the U.S. Food and...

A Paradigm Shift in Oncology: Revolutionary Brush Test Promises One-Hour Oral Cancer Detection a-paradigm-shift-in-oncology-revolutionary-brush-test-promises-one-hour-oral-cancer-detection

A Paradigm Shift in Oncology: Revolutionary Brush Test Promises One-Hour Oral Cancer Detection

Nana Wu July 16, 2026

In a landmark development for global oncology, researchers led by Queen Mary University of London have successfully...

Navigating the New Frontier: The Evolution of BCMA-Targeted Therapies in Multiple Myeloma navigating-the-new-frontier-the-evolution-of-bcma-targeted-therapies-in-multiple-myeloma

Navigating the New Frontier: The Evolution of BCMA-Targeted Therapies in Multiple Myeloma

Raul Delapena Setiawan July 15, 2026

The treatment landscape for multiple myeloma (MM) is currently undergoing its most significant paradigm shift since the...

The Biological Vulnerability: Defining the Critical Postpartum Window for Breast Cancer Risk the-biological-vulnerability-defining-the-critical-postpartum-window-for-breast-cancer-risk

The Biological Vulnerability: Defining the Critical Postpartum Window for Breast Cancer Risk

Azzam Bilal Chamdy July 15, 2026

New research from the UCLA Health Jonsson Comprehensive Cancer Centre has cast a significant light on the...

The Liquid Biopsy Revolution: Redefining Early-Stage Breast Cancer Surveillance Through MRD Testing the-liquid-biopsy-revolution-redefining-early-stage-breast-cancer-surveillance-through-mrd-testing

The Liquid Biopsy Revolution: Redefining Early-Stage Breast Cancer Surveillance Through MRD Testing

Azzam Bilal Chamdy July 15, 2026

The landscape of breast cancer management is undergoing a seismic shift. For decades, the standard of care...

Precision Medicine Breakthrough: i31-SLNB Test Outperforms Traditional Nomograms in Melanoma Management precision-medicine-breakthrough-i31-slnb-test-outperforms-traditional-nomograms-in-melanoma-management

Precision Medicine Breakthrough: i31-SLNB Test Outperforms Traditional Nomograms in Melanoma Management

Nana July 14, 2026

Main Facts: A Paradigm Shift in Cutaneous Melanoma Care In the evolving landscape of oncological precision medicine,...

A New Horizon in Hematology: Triple-Combination Therapy Sets New Benchmark for Relapsed/Refractory CLL $a-new-horizon-in-hematology-triple-combination-therapy-sets-new-benchmark-for-relapsed-refractory-cll$

A New Horizon in Hematology: Triple-Combination Therapy Sets New Benchmark for Relapsed/Refractory CLL

Nana July 14, 2026

Introduction: A Paradigm Shift in Chronic Lymphocytic Leukemia Treatment In the landscape of oncology, few challenges are...

Clinical Oncology Education

Revolutionizing Oncology: The Global Roll-Out of AI-Powered Bone Imaging for Advanced Cancer

FDA Expands Scope of Palbociclib: A New Maintenance Strategy for HR+/HER2+ Metastatic Breast Cancer

Breakthrough in Pediatric Oncology: Combining Radiopharmaceuticals and CAR T-Cell Therapy to Defeat Solid Tumors

FDA Approves Subcutaneous Isatuximab-irfc: A New Era in Multiple Myeloma Treatment

A Paradigm Shift in Oncology: Revolutionary Brush Test Promises One-Hour Oral Cancer Detection

Navigating the New Frontier: The Evolution of BCMA-Targeted Therapies in Multiple Myeloma

The Biological Vulnerability: Defining the Critical Postpartum Window for Breast Cancer Risk

The Liquid Biopsy Revolution: Redefining Early-Stage Breast Cancer Surveillance Through MRD Testing

Precision Medicine Breakthrough: i31-SLNB Test Outperforms Traditional Nomograms in Melanoma Management

A New Horizon in Hematology: Triple-Combination Therapy Sets New Benchmark for Relapsed/Refractory CLL

You may have missed

The Dismantling of U.S. Global Health: A Post-Mortem on the Restructuring of Maternal and Child Health Initiatives

The Yoga Mat as a Social Conduit: How One Prop Transforms Urban Isolation into Community

Groundbreaking Study Uncovers Specific Link Between Linoleic Acid and Aggressive Breast Cancer Subtype, Paving Way for New Strategies

From Diabetes to MASH: The Evolving Science and Supply Chain Behind the GLP-1 Revolution